


Pilot study of 5-hour molecular test accurately distinguishes malignant and benign breast tumors: Novel technology based on epigenetic alterations could shorten wait for a definitive diagnosis in resource-poor settings

Targeting old bottleneck reveals new anticancer drug strategy: Hot target SIRT2 regulates ribonucleotide reductase

Imprinted spheres fight breast cancer: Inhibition of HER2 on tumor cells by molecularly imprinted nanoparticles
